Free beta access. 50 free AI tokens each week. Optional top-ups available. See what is included
← SearchNorthwestern2023Affirmative
Opening Word document…

Innovation into non-traditional medical products prevents pandemics from taking hold in the first instance

Carolyn Shore 17, Pew Charitable trust Anti-Biotic Resistance Project, Director, Forum on Drug Discovery, Development, and Translation - ‎The National Academies of Sciences, Engineering, and Medicine. 5/22/17, “Nontraditional Products in Development to Treat or Prevent Bacterial Infections” http://www.pewtrusts.org/en/research-and-analysis/analysis/2017/05/17/nontraditional-products-in-development-to-treat-or-prevent-bacterial-infections

While antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—remains essential to combating antibiotic resistance, “outside-the-box” approaches to preventing and treating bacterial infections are also needed. Such nontraditional approaches encompass a variety of products, including:

Well-known medical interventions, such as vaccines and immunotherapies, that have been proved effective in treating other types of disease and may also hold promise for the prevention or treatment of systemic (throughout the body) bacterial infections.

Entirely new types of therapies that have never been approved for use in human medicine. For example, products that disarm harmful pathogens to neutralize their threat to patients, or products that replace harmful bacteria with “healthy” bacteria to alleviate disease.

Nontraditional products are unlikely to fully substitute or replace antibiotic use but could provide new treatment options for patients through combined use with antibiotics or as a means of preventing an infection from taking hold. Questions remain regarding how nontraditional products should be tested for safety and efficacy, and how they could be used appropriately in the clinical setting.

To shed light on the development of these types of products and evaluate public policies to spur innovation, The Pew Charitable Trusts assessed nontraditional products for the treatment of systemic bacterial infection in clinical testing for the U.S. market. The list, which will be updated regularly, identifies each product and its manufacturer, type of approach, potential targets, and stage in the clinical development process. The list does not include products that are in development but not yet being tested in humans. (See the methodology below for the criteria used to select the nontraditional products.)

Findings

The current assessment of the pipeline shows that 32 nontraditional products are in clinical development for the U.S. market. Unlike many antibiotics in development, most nontraditional products are active against a limited range of pathogens. As of March 2017:

Of the 32 nontraditional products in development, seven were in Phase 1 clinical trials, 21 were in Phase 2 clinical trials, three were in Phase 3 clinical trials, and one was recently approved. (See the glossary of terms for descriptions of each phase.)

Sign in to recut, update, or save this card.